65,437 trials
Chagas Disease
Primary: Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance — 16.8 percentage of fibrosis
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Fatty Liver
Primary: Number of Study Participants With Adverse Events — 0; 0 Participants
Colorectal Cancers
Primary: Overall Survival — 9.25 months
Brain and Central Nervous System Tumors
Primary: Number of Participants With Treatment-Related Adverse Events of Any Grade — 34 Participants
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
Bacterial Enteritis
Primary: Bacterial Elimination Rate (BER) in the CDI and EI Groups — 100.0; 72.7; 90.0; 87.5 percentage of participants
Allergic Rhinitis · Allergic Conjunctivitis
Primary: Change in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16) — -0.7; 0.3; -2.8; 0.9 units on a scale
Acute Pain
Primary: TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose) — 13.0; 9.2; 1.9 5-point Verbal Rating Scale
Cancer of Bladder
Primary: Number of Patients With Incidence of Intraoperative Adductor Spasm — 1; 5 Participants
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
Primary Sjögren's Syndrome
Primary: Proportion of Participants With a 1 Point or Greater Change on the Salivary Gland Ultrasound (SGUS) Score for Parotid and Submandibular Glands — 0; 0 Participants
Septic Shock
Primary: Endpoints for Primary Objective (Safety and Tolerability of Adrecizumab: Mortality) — 63.1453; 63.1578; 64.5744; 63.9809 days
Post Operative Pain
Primary: Anterior Knee Pain — 2.4; 1.9 units on a scale — p=0.55
Patient Readmission · Adverse Drug Event · Cost
Primary: Number of Participants With Hospital Readmission — 23; 21; 35 Participants